{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:08:24Z","timestamp":1787069304343,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,2,2]],"date-time":"2018-02-02T00:00:00Z","timestamp":1517529600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s40273-017-0605-2","type":"journal-article","created":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T20:40:12Z","timestamp":1517517612000},"page":"603-612","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["A Decision-Analytic Model to Assess the Cost-Effectiveness of Etelcalcetide vs. Cinacalcet"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3189-409X","authenticated-orcid":false,"given":"Bj\u00f6rn","family":"Stollenwerk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Iannazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Akehurst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Adena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Briggs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastian","family":"Dehmel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Parfrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasily","family":"Belozeroff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,2]]},"reference":[{"issue":"3","key":"605_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/j.0894-0959.2004.17308.x","volume":"17","author":"WG Goodman","year":"2004","unstructured":"Goodman WG. The consequences of uncontrolled secondary hyperparathyroidism and its treatment in chronic kidney disease. Semin Dial. 2004;17(3):209\u201316.","journal-title":"Semin Dial"},{"key":"605_CR2","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1038\/sj.ki.5001754","volume":"70","author":"M Jadoul","year":"2006","unstructured":"Jadoul M, Albert JM, Akiba T, et al. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2006;70:1358\u201366.","journal-title":"Kidney Int"},{"key":"605_CR3","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","volume":"15","author":"GA Block","year":"2004","unstructured":"Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15:2208\u201318.","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"605_CR4","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1093\/ndt\/gfq219","volume":"26","author":"J Floege","year":"2011","unstructured":"Floege J, Kim J, Ireland E, Chazot C, Drueke T, de Francisco A, Kronenberg F, Marcelli D, Passlick-Deetjen J, Schernthaner G, Fouqueray B, Wheeler DC, Investigators ARO. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant. 2011;26(6):1948\u201355.","journal-title":"Nephrol Dial Transplant"},{"key":"605_CR5","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/1471-2369-14-88","volume":"14","author":"JL Natoli","year":"2013","unstructured":"Natoli JL, Boer R, Nathanson BH, Miller RM, Chiroli S, Goodman WG, Belozeroff V. Is there an association between elevated or low serum levels of phosphorus, parathyroid hormone, and calcium and mortality in patients with end stage renal disease? A meta-analysis. BMC Nephrol. 2013;14:88.","journal-title":"BMC Nephrol"},{"key":"605_CR6","doi-asserted-by":"publisher","first-page":"184321","DOI":"10.1155\/2015\/184321","volume":"2015","author":"E Hedgeman","year":"2015","unstructured":"Hedgeman E, Lipworth L, Lowe K, Saran R, Do T, Fryzek J. International burden of chronic kidney disease and secondary hyperparathyroidism: a systematic review of the literature and available data. Int J Nephrol. 2015;2015:184321.","journal-title":"Int J Nephrol."},{"key":"605_CR7","doi-asserted-by":"crossref","unstructured":"KDIGO group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease\u2014mineral and bone disorder. Kidney Int Suppl. 2017;7(1):1\u201359.","DOI":"10.1016\/j.kisu.2017.04.001"},{"issue":"1","key":"605_CR8","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1186\/s12882-017-0665-8","volume":"18","author":"B Hauber","year":"2017","unstructured":"Hauber B, Caloyeras J, Posner J, Brommage D, Belozeroff V, Cooper K. Hemodialysis patients\u2019 preferences for the management of secondary hyperparathyroidism. BMC Nephrol. 2017;18(1):254.","journal-title":"BMC Nephrol."},{"issue":"2","key":"605_CR9","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1001\/jama.2016.19456","volume":"317","author":"GA Block","year":"2017","unstructured":"Block GA, Bushinsky DA, Cunningham J, Drueke TB, Ketteler M, Kewalramani R, Martin KJ, Mix TC, Moe SM, Patel UD, Silver J, Spiegel DM, Sterling L, Walsh L, Chertow GM. Effect of etelcalcetide vs placebo on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: two randomized clinical trials. JAMA. 2017;317(2):146\u201355. https:\/\/doi.org\/10.1001\/jama.2016.19456 .","journal-title":"JAMA."},{"issue":"2","key":"605_CR10","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1001\/jama.2016.19468","volume":"317","author":"GA Block","year":"2017","unstructured":"Block GA, Bushinsky DA, Cheng S, Cunningham J, Dehmel B, Drueke TB, Ketteler M, Kewalramani R, Martin KJ, Moe SM, Patel UD, Silver J, Sun Y, Wang H, Chertow GM. Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial. JAMA. 2017;317(2):156\u201364. https:\/\/doi.org\/10.1001\/jama.2016.19468 .","journal-title":"JAMA."},{"issue":"5","key":"605_CR11","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1177\/0272989X12455463","volume":"32","author":"U Siebert","year":"2012","unstructured":"Siebert U, et al. State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3. Med Decis Making. 2012;32(5):690\u2013700.","journal-title":"Med Decis Making"},{"key":"605_CR12","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jval.2013.02.002","volume":"16","author":"D Husereau","year":"2013","unstructured":"Husereau D, Drummond M, Petrou S, et al. Consolidated health economic evaluation reporting standards (CHEERS)\u2014explanation and elaboration: a report of the ISPOR health economic evaluations publication guidelines good reporting practices task force. Value Health. 2013;16:231\u201350.","journal-title":"Value Health"},{"issue":"8","key":"605_CR13","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.jval.2015.08.007","volume":"18","author":"V Belozeroff","year":"2015","unstructured":"Belozeroff V, Chertow GM, Graham CN, Dehmel B, Parfrey PS, Briggs AH. Economic evaluation of cinacalcet in the United States: the EVOLVE trial. Value Health. 2015;18(8):1079\u201387.","journal-title":"Value Health."},{"key":"605_CR14","unstructured":"Garside R, Pitt M, Anderson R, Mealing S, Roome C, Snaith A, D\u2019Souza R, Welch K, Stein K. The effectiveness and cost-effectiveness of cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients on dialysis: a systematic review and economic evaluation. Health Technol Assess. 2007;11(18):iii, xi\u2013xiii, 1\u2013167."},{"key":"605_CR15","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s40273-015-0327-2","volume":"34","author":"P Vemer","year":"2016","unstructured":"Vemer P, Corro Ramos P, van Voorn GAK, Al MJ, Feenstra TL. AdViSHE: a validation-assessment tool of health-economic models for decision makers and model users. PharmacoEconomics. 2016;34:349\u201361.","journal-title":"PharmacoEconomics"},{"issue":"4","key":"605_CR16","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1177\/0272989X09340585","volume":"29","author":"JJ Barendregt","year":"2009","unstructured":"Barendregt JJ. The half-cycle correction: banish rather than explain it. Med Decis Making. 2009;29(4):500\u20132.","journal-title":"Med Decis Making"},{"issue":"3","key":"605_CR17","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1177\/0272989X14520719","volume":"34","author":"DM Naimark","year":"2014","unstructured":"Naimark DM, Kabboul NN, Krahn MD. Response to \u201cthe life table method of half-cycle correction: getting it right\u201d. Med Decis Making. 2014;34(3):286\u20137.","journal-title":"Med Decis Making"},{"issue":"26","key":"605_CR18","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","volume":"367","author":"GM Chertow","year":"2012","unstructured":"Evolve Trial Investigators, Chertow GM, Block GA, Correa-Rotter R, Drueke TB, Floege J, Goodman WG, Herzog CA, Kubo Y, London GM, Mahaffey KW, Mix TC, Moe SM, Trotman ML, Wheeler DC, Parfrey PS. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012;367(26):2482\u201394.","journal-title":"N Engl J Med"},{"issue":"6","key":"605_CR19","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1681\/ASN.2014040414","volume":"26","author":"SM Moe","year":"2015","unstructured":"Moe SM, et al. Effects of cinacalcet on fracture events in patients receiving hemodialysis: the EVOLVE trial. J Am Soc Nephrol. 2015;26(6):1466\u201375.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"605_CR20","doi-asserted-by":"publisher","first-page":"509","DOI":"10.3111\/13696998.2012.664799","volume":"15","author":"R Boer","year":"2012","unstructured":"Boer R, Lalla AM, Belozeroff V. Cost-effectiveness of cinacalcet in secondary hyperparathyroidism in the United States. J Med Econ. 2012;15(3):509\u201320.","journal-title":"J Med Econ."},{"key":"605_CR21","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s12882-015-0174-6","volume":"16","author":"BD Reams","year":"2015","unstructured":"Reams BD, et al. Dynamics of cinacalcet use and biochemical control in hemodialysis patients: a retrospective new-user cohort design. BMC Nephrol. 2015;16:175.","journal-title":"BMC Nephrol"},{"issue":"8","key":"605_CR22","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1177\/0272989X16638312","volume":"36","author":"AH Briggs","year":"2016","unstructured":"Briggs AH, Parfrey PS, Khan N, Tseng S, Dehmel B, Kubo Y, Chertow GM, Belozeroff V. Analyzing health-related quality of life in the EVOLVE trial: the joint impact of treatment and clinical events. Med Decis Making. 2016;36(8):965\u201372.","journal-title":"Med Decis Making."},{"issue":"3","key":"605_CR23","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1177\/0272989X09347015","volume":"30","author":"B Stollenwerk","year":"2010","unstructured":"Stollenwerk B, et al. Uncertainty assessment of input parameters for economic evaluation: Gauss\u2019s error propagation, an alternative to established methods. Med Decis Making. 2010;30(3):304\u201313.","journal-title":"Med Decis Making"},{"issue":"2","key":"605_CR24","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2165\/11597980-000000000-00000","volume":"10","author":"S Iannazzo","year":"2012","unstructured":"Iannazzo S, Carsi M, Chiroli S. A cost-utility analysis of cinacalcet in secondary hyperparathyroidism in five European countries. Appl Health Econ Health Policy. 2012;10(2):127\u201338.","journal-title":"Appl Health Econ Health Policy."},{"issue":"4","key":"605_CR25","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s40261-014-0264-4","volume":"35","author":"M Nuijten","year":"2015","unstructured":"Nuijten M, Roggeri DP, Roggeri A, Novelli P, Marshall TS. Health economic evaluation of paricalcitol(\u00ae) versus cinacalcet\u00a0+\u00a0calcitriol (oral) in Italy. Clin Drug Investig. 2015;35(4):229\u201338.","journal-title":"Clin Drug Investig."},{"issue":"11","key":"605_CR26","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.2165\/11538600-000000000-00000","volume":"28","author":"M Eandi","year":"2010","unstructured":"Eandi M, Pradelli L, Iannazzo S, Chiroli S, Pontoriero G. Economic evaluation of cinacalcet in the treatment of secondary hyperparathyroidism in Italy. Pharmacoeconomics. 2010;28(11):1041\u201354.","journal-title":"Pharmacoeconomics."},{"issue":"5","key":"605_CR27","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1111\/j.1524-4733.2008.00329.x","volume":"11","author":"JA Ray","year":"2008","unstructured":"Ray JA, Borker R, Barber B, Valentine WJ, Belozeroff V, Palmer AJ. Cost-effectiveness of early versus late cinacalcet treatment in addition to standard care for secondary renal hyperparathyroidism in the USA. Value Health. 2008;11(5):800\u20138.","journal-title":"Value Health."},{"issue":"12","key":"605_CR28","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.2215\/CJN.04100609","volume":"4","author":"WL St Peter","year":"2009","unstructured":"St Peter WL, Fan Q, Weinhandl E, Liu J. Economic evaluation of sevelamer versus calcium-based phosphate binders in hemodialysis patients: a secondary analysis using centers for Medicare & Medicaid services data. Clin J Am Soc Nephrol. 2009;4(12):1954\u201361.","journal-title":"Clin J Am Soc Nephrol."},{"issue":"5","key":"605_CR29","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1093\/ndt\/gfv068","volume":"30","author":"G Tripepi","year":"2015","unstructured":"Tripepi G, Heinze G, Jager KJ, Stel VS, Dekker FW, Zoccali C. Lag-censoring analysis: lights and shades. Nephrol Dial Transplant. 2015;30(5):700\u20135.","journal-title":"Nephrol Dial Transplant."},{"issue":"1","key":"605_CR30","first-page":"248","volume":"13","author":"V Belozeroff","year":"2013","unstructured":"Belozeroff V, Cooper K, Hess G, Chang CL. Healthcare use and costs before and after parathyroidectomy in patients on dialysis. BMC HSR. 2013;13(1):248.","journal-title":"BMC HSR."},{"issue":"11","key":"605_CR31","doi-asserted-by":"publisher","first-page":"981","DOI":"10.2165\/11599390-000000000-00000","volume":"30","author":"DT Grima","year":"2012","unstructured":"Grima DT, et al. Cost-effectiveness analysis of therapies for chronic kidney disease patients on dialysis: a case for excluding dialysis costs. Pharmacoeconomics. 2012;30(11):981\u20139.","journal-title":"Pharmacoeconomics"},{"key":"605_CR32","doi-asserted-by":"crossref","unstructured":"Gutzwiller FS, et al. Cost effectiveness of sucroferric oxyhydroxide compared with sevelamer carbonate in the treatment of hyperphosphataemia in patients receiving dialysis, from the perspective of the National Health Service in Scotland. Pharmacoeconomics. 2015;33(12):1311\u201324.","DOI":"10.1007\/s40273-015-0320-9"},{"issue":"5","key":"605_CR33","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s40620-014-0122-8","volume":"28","author":"M Ruggeri","year":"2015","unstructured":"Ruggeri M, et al. Sevelamer is cost effective versus calcium carbonate for the first-line treatment of hyperphosphatemia in new patients to hemodialysis: a patient-level economic evaluation of the INDEPENDENT-HD study. J Nephrol. 2015;28(5):593\u2013602.","journal-title":"J Nephrol"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40273-017-0605-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-017-0605-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-017-0605-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T00:58:20Z","timestamp":1570669100000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40273-017-0605-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,2]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["605"],"URL":"https:\/\/doi.org\/10.1007\/s40273-017-0605-2","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,2]]},"assertion":[{"value":"2 February 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Financial support for this study was provided by Amgen. The funding agreement ensured the authors\u2019 independence in designing the study, interpreting the data, writing, and publishing the report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"SI, MA, RA, PP and AB contributed to the development of the study through a consulting agreement with Amgen. BS, BD and VB are employed by Amgen and holders of Amgen stock and\/or stock options.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval for the version to be published. The authors thank the Amgen biostatistical department for the support provided.\u00a0Furthermore, we thank Kirsten Westerhout for valuable feedback within the later stages of the model development.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}